ArticleFrontiers in oncology2026
RPLP0 identified as a ferroptosis regulator in HCC through pan-cancer analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: RPLP0, a ribosomal protein critical for protein biosynthesis, has emerged as a multifaceted oncoprotein through its regulation of programmed cell death (PCD) pathways. Despite its established roles in tumorigenesis, its pan-cancer relevance and ferroptosis regulatory function remains unexplored. Methods: Bioinformatics analyses utilized TCGA, GTEx, GEPIA, UALCAN, HPA, cBioPortal, TISIDB, FerrDb, BioGRID, HitPredict, and R Studio. Experimental validation in hepatocellular carcinoma (HCC) included RT-qPCR, IHC, CCK8, transwell, and colony formation assays. Ferroptosis was assessed via lipid ROS, ferrous iron, and GSH detection. Results: Our comprehensive pan-cancer analysis revealed conserved RPLP0 upregulation across malignancies, positively associated with adverse clinical outcomes. Genomic profiling identified recurrent RPLP0 alterations, while tumor microenvironment analyses demonstrated significant negative correlations between RPLP0 expression and immune cell infiltration. Focusing on hepatocellular carcinoma (HCC), experimental validation confirmed that RPLP0 depletion suppressed tumor progression via ferroptosis induction through metabolic and oxidative cascades, and RPLP0 was positively correlated with key ferroptosis suppressor GPX4. Conclusions: This work advances the understanding of ribosomal protein biology by establishing RPLP0 as a pan-cancer biomarker bridging ribosome function with immune evasion, unveiling its canonical role in HCC progression, and discovering RPLP0-GPX4-mediated ferroptosis resistance axis, providing a novel therapeutic paradigm for aggressive cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.